Additional single and combination agent trials in TNBC, ER+ breast cancers, small-cell and non-small-cell lung cancers, castration-resistant prostate cancer, pancreatic ductal adenocarcinoma, colorectal cancer, neuroblastoma and MYCN-driven solid tumors are summarized in Table 2. Here, MYCN is linked to neuroblastoma.